Sweden’s most promising startups
Sting has contributed to the development of over 200 companies, primarily in ICT, Internet/media, cleantech, sustainability, health and life science. We offer two programmes: Sting Accelerate and Sting Incubate. Here you can read about the companies who are currently a part of Sting and also get to know some more about our alumni companies.
Every year there are 3.4 billion attempts at gaining intravenous access in the U.S. and Europe. Despite this being the most common invasive procedure in healthcare, up to every third attempt fails. The failed attempts hurt patients, waste nurses’ time and cost over $20 billion annually. Ortrud Medical is developing an innovative medical device that facilitates intravenous access and decreases the fail rate.